View Older Stories View More Recent Stories
-
Axsome Therapeutics (AXSM) Enters $570M Term Loan and Revolving Credit Facility with Blackstone
-
Axsome Therapeutics (AXSM) PT Lowered to $180 at H.C. Wainwright
-
Axsome Therapeutics (AXSM) PT Raised to $176 at BofA Securities
-
Axsome Therapeutics (AXSM) Tops Q1 EPS by 8c
-
Axsome Therapeutics (AXSM) PT Raised to $193 at RBC Capital
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Jefferies Starts Axsome Therapeutics (AXSM) at Buy
-
Axsome Therapeutics (AXSM) Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05
-
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
-
Mizuho on Axsome Therapeutics (AXSM): 'we recommend being opportunistic on any continued weakness'
-
Guggenheim on Axsome Therapeutics (AXSM): 'This does not come as a surprise to us'
-
BofA on Axsome Therapeutics (AXSM): 'post IP resolution we expect Axsome shares to benefit from scarcity value of high growth'
-
Axsome Therapeutics (AXSM) Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol
-
Piper Sandler Reiterates Overweight on Axsome Therapeutics (AXSM) Following FOCUS Results
-
Axsome Therapeutics (AXSM) PT Raised to $216 at Mizuho
-
Guggenheim Defending Axsome Therapeutics (AXSM), 'buyers of AXSM shares on today's weakness'
-
Axsome Therapeutics (AXSM) Announces FOCUS Phase 3 Trial of Solriamfetol Achieves Primary Endpoint
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Cantor Biotech industry report, buying value in RevGens
-
Piper Sandler 'Staying Bullish' on Axsome Therapeutics (AXSM)
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) Settles Sunosi Patent Litigation with Hikma Pharmaceuticals USA
-
Axsome Therapeutics (AXSM) Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
-
Axsome Therapeutics (AXSM) PT Raised to $212 at Mizuho, Top Pick
-
Axsome Therapeutics (AXSM) Announces SYMBRAVO Achieves Primary Endpoint in the EMERGE Phase 3 Trial
-
Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $192 as RBC Capital Sees 'Further Room For Upside'
-
Axsome Therapeutics (AXSM) PT Raised to $153 at Needham
-
Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities
-
Axsome Therapeutics (AXSM) Misses Q4 EPS by 58c
-
Axsome Therapeutics (AXSM) PT Raised to $133 at UBS
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $195 at Mizuho
-
Axsome Therapeutics (AXSM) PT Raised to $190 at TD Cowen, Top Pick
-
Deutsche Bank Starts Axsome Therapeutics (AXSM) at Buy
-
Axsome Therapeutics (AXSM) PT Raised to $167 at BofA Securities
-
Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) Announces Settlement Agreement Resolving AUVELITY Patent Litigation
-
Axsome Therapeutics (AXSM) PT Raised to $143 at RBC Following Symbravo's Approval
-
Axsome Therapeutics (AXSM) PT Raised to $190 at Truist, Citing 'Symbravo's Bright Commercial Prospects'
-
Axsome Therapeutics (AXSM) PT Raised to $137 at Mizuho
-
Axsome Therapeutics (AXSM) Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader
-
Axsome Therapeutics (AXSM) PT Raised to $190 at H.C. Wainwright
-
Axsome Therapeutics (AXSM) Announces FDA Approval of SYMBRAVO for the Acute Treatment of Migraine with or without Aura in Adults
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Axsome Therapeutics (AXSM) PT Raised to $155 at TD Cowen
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $180 at Truist, Reflecting Raised AXS-05 Estimates
